التعريفات والمصطلحات الطبية في مجال تمريض الأورام

  Croal B. The Communication of Critical and Unexpected Pathology Results. London: The Royal College of Pathologists; 2017. Available at: https://www.rcpath.org/uploads/assets/bb86b370-1545-4c5a-b5826a2c431934f5/The-communication-of-critical-and-unexpected-pathology-results.pdf  Accessed August 2019

      .   National Cancer Institute. Tumor Markers in Common Use. 2019. Available at:  https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list  Accessed August 2019.

^-  American Association for Clinical Chemistry. Lab Tests Online. 2019. Available at: https://labtestsonline.org/articles/patient-tools  Accessed August 2019.

       ^-NeoGenomics. BTK Inhibitor Acquired Resistance Panel. 2019. Available at: https://neogenomics.com/test-menu/btk-inhibitor-acquired-resistance-panel  Accessed August 2019. 

       National Cancer Institute. BRCA Mutations: Cancer Risk and Genetic Testing. 2019. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1  Accessed August 2019.

        Naeim F, Rao PN, Son SX, Phan RT. Atlas of Hematology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. 2nd ed. Elsevier, Inc.; 2018. https://doi.org/10.1016/C2015-0-05997-4.

-  Pernick N. CD25. Pathology Outlines. 2013. Available at: https://www.pathologyoutlines.com/topic/cdmarkerscd25.html  Accessed August 2019. 

        Jain N, O’Brien S. Chronic Lymphocytic Leukemia with Deletion 17p: Emerging Treatment Options. 2012. Available at: https://www.cancernetwork.com/hematologic-malignancies/chronic-lymphocytic-leukemia-deletion-17p-emerging-treatment-options Accessed August 2019.

        Helsten T, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259-267. Available at: http://clincancerres.aacrjournals.org/content/22/1/259.full-text.pdf Accessed August 2019. 

       Genetics Home Reference. HRAS Gene. 2019. Available at: https://ghr.nlm.nih.gov/gene/HRAS# Accessed August 2019.

        Roychowhurdy M. Stains: Ki67 / MIB1. Pathology Outlines. 2019. Available

       Association of Oncology Nurse Navigators+. Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors. 2018. Available at: https://aonnonline.org/component/mams/?view=article&secid=180:faculty-perspectives-clinical-relevance-and-rationale-of-using-msi-h-dmmr-biomarkers-in-immunotherapy-of-colorectal-cancer-and-other-solid-tumors-part-3-of-a-4-part-series&artid=2068:clinical-relevance-and-rationale-of-using-msi-h-dmmr-biomarkers-in-immunotherapy-of-colorectal-cancer-and-other-solid-tumors   Accessed August 2019.